Comparative Antiproteinuric Efficacy of Ramipril and Cilnidipine in Diabetic Nephropathy: A Randomized Controlled Trial


PDF PDF

Keywords

Antiproteinuric
Cilnidipine
Diabetic nephropathy
Proteinuria
Ramipril

How to Cite

1.
Comparative Antiproteinuric Efficacy of Ramipril and Cilnidipine in Diabetic Nephropathy: A Randomized Controlled Trial. The Insight [Internet]. 2026 Nov. 16 [cited 2026 Nov. 17];9(03):1004-9. Available from: https://bdjournals.org/insight/article/view/1674

Abstract

Background: Diabetic nephropathy is a leading cause of end-stage kidney disease worldwide, with proteinuria serving as a key modifiable risk factor. Renin-angiotensin system blockade remains the standard antiproteinuric therapy, though alternative agents like cilnidipine may offer additional benefits through dual calcium channel blockade. Objective: To compare the antiproteinuric efficacy and safety of ramipril versus cilnidipine in adult patients with diabetic nephropathy. Methods & Materials: This interventional study was conducted at Bangabandhu Sheikh Mujib Medical University, Dhaka, from September 2019 to June 2020. Ninety-three patients with diabetic nephropathy (uACR ≥30 mg/g, eGFR ≥60 ml/min/1.73m², HbA1C ≤7%) were randomized to receive ramipril 5mg daily (n=48) or cilnidipine 10mg daily (n=45) for six months. We assessed urinary albumin-to-creatinine ratio, urinary total protein, blood pressure, serum creatinine, HbA1c, and adverse effects at baseline, 3 months, and 6 months. Data were analyzed using SPSS v26. Results: Baseline characteristics were comparable between groups. At six months, urinary albumin-to-creatinine ratio reduction was significantly greater in the cilnidipine group (1828.9±116.9 mg/g vs. 1190.5±98.7 mg/g, p=0.004). Urinary total protein reduction also favored cilnidipine (3.78±1.48 gm vs. 2.88±1.25 gm, p<0.001). Blood pressure, serum creatinine, and HbA1c showed no significant intergroup differences. Adverse effects were mild and comparable between groups. Conclusion: Cilnidipine demonstrates superior antiproteinuric efficacy compared with ramipril in patients with diabetic nephropathy, with a comparable safety profile. Cilnidipine may represent a valuable alternative for proteinuria reduction, particularly in patient's intolerant to renin-angiotensin system blockers.
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright (c) 2026 The Insight